TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B

Thermo Fisher Scientific balance sheet 1985–2026

Thermo Fisher Scientific had 6.06B USD in cash and short-term investments on 26 September 2026, against total debt of 41.37B USD: net debt of 35.31B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
5.46B9.85B4.02B8.08B8.52B4.48B10.33B2.40B2.10B1.34B786.00M
Short-term investments
600.00M253.00M1.56B0.000.000.000.000.000.000.000.00
6.06B10.11B5.58B8.08B8.52B4.48B10.33B2.40B2.10B1.34B786.00M
Cash growth
+70.93%+81.09%-30.97%-5.17%+90.40%-56.64%+330.39%+14.08%+57.53%+69.85%+73.86%
Receivables
9.63B10.57B9.63B9.66B9.43B8.95B6.47B4.95B4.60B3.88B3.05B
Inventory
5.64B5.43B4.98B5.09B5.63B5.05B4.03B3.37B3.01B2.97B2.21B
Other current assets
4.29B2.61B1.95B1.76B1.64B1.64B1.13B1.17B922.00M1.24B973.00M
Total current assets
25.62B28.71B22.14B24.59B25.23B20.11B21.96B11.89B10.63B9.42B7.02B
Property, plant and equipment
10.58B10.57B10.80B11.00B10.87B9.86B6.69B5.45B4.17B4.05B2.58B
Long-term investments
0.000.00560.00M59.00M155.00M73.00M65.00M35.00M53.00M34.00M37.00M
Goodwill and intangibles
72.34B65.20B61.39B60.69B58.67B62.07B38.77B39.73B40.33B41.97B35.30B
Goodwill
54.26B49.36B45.85B44.02B41.20B41.92B26.04B25.71B25.35B25.29B21.33B
Intangible assets
18.08B15.84B15.53B16.67B17.48B20.15B12.69B14.01B14.98B16.68B13.97B
Other non-current assets
5.70B5.87B2.44B2.38B2.22B3.00B1.57B1.28B1.06B1.19B974.90M
Total assets
114.23B110.34B97.32B98.73B97.15B95.12B69.05B58.38B56.23B56.67B45.91B
Accounts payable
3.09B3.62B3.08B2.87B3.38B2.87B2.18B1.92B1.62B1.43B926.20M
Deferred revenue
2.94B2.71B2.85B2.69B2.60B2.66B1.27B916.00M809.00M719.00M485.90M
Short-term debt
2.26B3.53B2.48B3.87B5.85B2.80B2.81B843.00M1.27B2.14B1.26B
Other current liabilities
3.81B0.002.94B2.98B3.08B2.68B2.13B1.51B1.47B1.85B1.32B
Total current liabilities
14.17B15.19B13.33B14.01B17.01B13.44B10.30B6.20B6.15B7.05B4.87B
Long-term debt
39.11B35.85B29.06B31.31B28.91B32.15B19.11B17.08B17.72B18.87B15.48B
Other non-current liabilities
4.71B4.27B1.61B1.90B1.75B2.10B1.94B2.08B2.16B2.57B1.57B
Lease obligations, current
0.000.000.000.000.000.000.000.000.000.00841.90M
Lease obligations, long-term
0.000.001.24B1.24B1.31B1.39B626.00M571.00M9.00M10.00M10.30M
Total liabilities
59.47B56.81B47.65B51.88B53.01B54.15B34.54B28.71B28.65B31.26B24.37B
Common stock and paid-in capital
447.00M445.00M444.00M442.00M441.00M439.00M437.00M434.00M432.00M428.00M415.10M
Retained earnings
63.74B59.16B53.10B47.36B41.91B35.43B28.12B22.09B18.70B15.91B13.93B
Accumulated other comprehensive income
-2.26B-2.45B-2.70B-3.22B-3.10B-2.33B-2.81B-2.68B-2.50B-2.00B-2.64B
Shareholders' equity
54.76B53.41B49.58B46.74B43.98B40.79B34.51B29.68B27.59B25.41B21.54B
Minority interest
6.00M129.00M87.00M107.00M170.00M184.00M10.00M0.000.000.000.00
41.37B39.39B32.78B36.42B36.07B36.34B22.55B18.49B18.99B21.01B16.63B
Net cash
-35.31B-29.28B-27.20B-28.34B-27.55B-31.86B-12.22B-16.09B-16.89B-19.67B-15.84B
Working capital
11.45B13.52B8.81B10.58B8.22B6.68B11.65B5.70B4.48B2.37B2.16B
Book value per share
147.61141.66129.46120.45111.62102.7586.4873.6467.9563.8554.20
Tangible book value
-17.58B-11.79B-11.80B-13.96B-14.70B-21.28B-4.26B-10.05B-12.74B-16.56B-13.76B
Tangible book value per share
-47.38-31.28-30.81-35.97-37.30-53.59-10.68-24.95-31.38-41.61-34.62
Current ratio
1.811.891.661.751.481.502.131.921.731.341.44
Debt to equity
0.760.740.660.780.820.890.650.620.690.830.77

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Thermo Fisher Scientific's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.